Eledon Pharmaceuticals (ELDN)
(Delayed Data from NSDQ)
$2.73 USD
-0.01 (-0.36%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $2.66 -0.07 (-2.56%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Eledon Pharmaceuticals, Inc. [ELDN]
Reports for Purchase
Showing records 1 - 20 ( 20 total )
Company: Eledon Pharmaceuticals, Inc.
Industry: Medical - Drugs
Updated Tegoprubart Results at ATC Continue to Support its First-Line Potential; Reiterate Buy and $16 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Eledon Pharmaceuticals, Inc.
Industry: Medical - Drugs
1Q24 Results and Update: Significant Tegoprubart Progress and Balance Sheet Strength
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Eledon Pharmaceuticals, Inc.
Industry: Medical - Drugs
Tegoprubart Continues to Show Safety in Organ Transplant; Reiterate Buy; Raising PT to $16
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Eledon Pharmaceuticals, Inc.
Industry: Medical - Drugs
Tegoprubart Again Impressive in Pig Kidney-to-Human Post-Transplant Maintenance
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Eledon Pharmaceuticals, Inc.
Industry: Medical - Drugs
3Q23 Results: Significant Tegoprubart Clinical Progress; Reiterate Buy Rating and $13 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Eledon Pharmaceuticals, Inc.
Industry: Medical - Drugs
Looking For Positive Tegorprubart Results at Kidney Week: Reiterate Buy With a New $13 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Eledon Pharmaceuticals, Inc.
Industry: Medical - Drugs
Tegoprubart Phase 1b Results in Kidney Transplant Highly Encouraging; Reiterate Buy Rating and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Eledon Pharmaceuticals, Inc.
Industry: Medical - Drugs
Collaboration Underway For Tegoprubart in Preclinical Xenotransplantation Studies; Reiterate Buy Rating and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Eledon Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Eledon Pharmaceuticals, Inc.
Industry: Medical - Drugs
Kidney Week - Filtering Through The Abstracts For Upcoming Meeting
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Eledon Pharmaceuticals, Inc.
Industry: Medical - Drugs
Tegoprubart Continued to Impress in 2Q22; Reiterate Buy Rating and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Eledon Pharmaceuticals, Inc.
Industry: Medical - Drugs
FDA Clears Tegoprubart IND for Kidney Transplant Recipients; Reiterate Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Eledon Pharmaceuticals, Inc.
Industry: Medical - Drugs
First Patient Dosed in Tegoprubart Phase1b in Kidney Transplantation; Reiterate Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Eledon Pharmaceuticals, Inc.
Industry: Medical - Drugs
Phase 2a Top-Line Data in ALS Met Primary Endpoints; Reiterate Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Eledon Pharmaceuticals, Inc.
Industry: Medical - Drugs
Rapidly Approaching the First of Four Tegoprubart Clinical Readouts in 2022; Reiterate Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Eledon Pharmaceuticals, Inc.
Industry: Medical - Drugs
Top-Line Data From Four Tegoprubart Clinical Programs Expected in 2022
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Eledon Pharmaceuticals, Inc.
Industry: Medical - Drugs
We Look to Multiple Positive AT-1501 Catalysts in 2022; Reiterate Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Eledon Pharmaceuticals, Inc.
Industry: Medical - Drugs
AT-1501 is Still Building Momentum for Multiple Catalysts in 2022; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Eledon Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Eledon Pharmaceuticals, Inc.
Industry: Medical - Drugs
Four Clinical Programs Set to Begin Revealing AT-1501?s Broad Therapeutic Potential; Reiterate Buy and $35 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
|